Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Phase Ib safety/efficacy data disclosed on SD-101 in treatment-naive hepatitis C

April 20, 2010

Fab-001 potently active against multiple staphylococcal strains in preclinical study

April 20, 2010

Phase II/III data on tafamidis meglumine in TTR-type familial amyloid polyneuropathy

April 20, 2010

Phase III data presented on sodium oxybate in fibromyalgia

April 20, 2010

Updated phase I data presented on JI-101 in solid tumors

April 19, 2010

Studies on progesterone caproate for prevention of preterm birth

April 19, 2010

Mirabegron well tolerated and improves overactive bladder variables in large study

April 19, 2010

Angiochem's EPiC platform yields anticancer drugs with improved brain penetration

April 19, 2010

Merck & Co.'s new GPR119 agonist lowers blood glucose in murine diabetes model

April 19, 2010

AZD-7295 well tolerated in HCV and active against HCV genotype 1b

April 16, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 5, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...